SCARDA: Japan’s Big Hope To Change Its Vaccine R&D Ecosystem
$1bn Support Now Expanded
Japan's SCARDA is building networks with academia and industry to support new vaccine development, while offering support through funding and knowledge. But is that enough to overcome the shortcomings highlighted by the pandemic?
You may also be interested in...
Twice-daily danuglipron reduced weight in a Phase IIb trial but with a poor side-effect profile and high discontinuation rates. Pfizer is working on a once-daily formulation it hopes will offer better tolerability.
A new state-supported scheme is to provide funding for R&D programs at Japanese bioventures, with up to JPY10bn available for each project. Eight selected VCs will fund one-third of the total, with the government to provide the rest.
The list including eight types of diseases such as flu and coronavirus infection, smallpox will be sent to SCARDA to determine which domestic vaccine development projects by pharmaceutical firms are to be funded. Some participants at the Ministry of Health, Labour and Welfare’s discussion insisted on continuous monitoring.